» Articles » PMID: 36451111

Prediction of Radiosensitivity and Radiocurability Using a Novel Supervised Artificial Neural Network

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Nov 30
PMID 36451111
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiotherapy has been widely used to treat various cancers, but its efficacy depends on the individual involved. Traditional gene-based machine-learning models have been widely used to predict radiosensitivity. However, there is still a lack of emerging powerful models, artificial neural networks (ANN), in the practice of gene-based radiosensitivity prediction. In addition, ANN may overfit and learn biologically irrelevant features.

Methods: We developed a novel ANN with Selective Connection based on Gene Patterns (namely ANN-SCGP) to predict radiosensitivity and radiocurability. We creatively used gene patterns (gene similarity or gene interaction information) to control the "on-off" of the first layer of weights, enabling the low-dimensional features to learn the gene pattern information. ANN-SCGP was trained and tested in 82 cell lines and 1,101 patients from the 11 pan-cancer cohorts.

Results: For survival fraction at 2 Gy, the root mean squared errors (RMSE) of prediction in ANN-SCGP was the smallest among all algorithms (mean RMSE: 0.1587-0.1654). For radiocurability, ANN-SCGP achieved the first and second largest C-index in the 12/20 and 4/20 tests, respectively. The low dimensional output of ANN-SCGP reproduced the patterns of gene similarity. Moreover, the pan-cancer analysis indicated that immune signals and DNA damage responses were associated with radiocurability.

Conclusions: As a model including gene pattern information, ANN-SCGP had superior prediction abilities than traditional models. Our work provided novel insights into radiosensitivity and radiocurability.

Citing Articles

Integrating Omics Data and AI for Cancer Diagnosis and Prognosis.

Ozaki Y, Broughton P, Abdollahi H, Valafar H, Blenda A Cancers (Basel). 2024; 16(13).

PMID: 39001510 PMC: 11240413. DOI: 10.3390/cancers16132448.

References
1.
Sjostrom M, Staaf J, Eden P, Warnberg F, Bergh J, Malmstrom P . Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Res. 2018; 20(1):64. PMC: 6033283. DOI: 10.1186/s13058-018-0978-y. View

2.
Shedden K, Taylor J, Enkemann S, Tsao M, Yeatman T, Gerald W . Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008; 14(8):822-7. PMC: 2667337. DOI: 10.1038/nm.1790. View

3.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

4.
Weathers S, Gilbert M . Current challenges in designing GBM trials for immunotherapy. J Neurooncol. 2015; 123(3):331-7. DOI: 10.1007/s11060-015-1716-2. View

5.
Xie Y, Xiao Y, Liu Y, Lu X, Wang Z, Sun S . Construction of a novel radiosensitivity- and ferroptosis-associated gene signature for prognosis prediction in gliomas. J Cancer. 2022; 13(8):2683-2693. PMC: 9174846. DOI: 10.7150/jca.72893. View